Ruiyang Tian

TL;DR: NtAI, a genomic measure of unfaithfully repaired DNA, may identify cancer patients likely to benefit from treatments targeting defective DNA repair, and suggests impaired DNA repair in patients treated with platinum-based chemotherapy.

TL;DR: The results suggest that 8q22 amplification and overexpression of LAPTM4B and YWHAZ contribute to de novo chemoresistance to anthracyclines and are permissive for metastatic recurrence.

TL;DR: The authors' analysis revealed an LOH cluster with lower treatment resistance and a significant correlation between LOH burden and PFS, which may indicate vulnerability to treatment targeting DNA repair, such as PARP1 inhibitors.

TL;DR: It is indicated that LAPTM4B is required for lysosome homeostasis, acidification, and function, and that LAPS4B renders tumor cells resistant to lysOSome-mediated cell death triggered by environmental and genotoxic stresses.

TL;DR: The findings suggest that many of the newer therapies for BRCA1 breast cancers designed to exploit the BRCa1 deficiency in these cancers may also be effective in ER+ cancers that develop in this population.